Glucagon-like peptide 1 receptor agonists are not associated with an increased risk of ileus or intestinal obstruction in patients with inflammatory bowel disease: a danish nationwide cohort study
The University of Tennessee in Knoxville and Iowa State University in Ames are among the colleges with mixed use projects underway next to existing stadiums and arenas
Anything from lifestyle changes to mental health disorders can trigger sudden weight loss, but 72% of cases stem from medical conditions
September 25, 2024: Novo Nordisk Faces Senate Scrutiny Over Ozempic Pricing and Safety Concerns Novo Nordisk, the company that manufactures Ozempic, has recently come under fire from the United States Government for its excessive pricing, with significantly lower costs for Europeans and other countries using the same drug
The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities investor.lilly.com/news-releases/ The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities investor.lilly.com/news-releases/ 28.7% weight loss at 68 weeks is unprecedented but here's what concerns me about the real-world rollout
